Veozah: the first nonhormonal treatment for menopause hot flashes
Published · Researched 2026-09-22
What happened (dated facts)
On May 12, 2023, the U.S. FDA approved Veozah (fezolinetant), the first NK3-receptor antagonist — and the first nonhormonal treatment — for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) of menopause. In Phase 3 trials, it significantly reduced both the frequency and severity of hot flashes versus placebo. For women who cannot or prefer not to take hormone therapy, it created the first targeted nonhormonal option. (The drug carries liver-safety labeling; patients need baseline and periodic liver blood tests — the current label should be checked before any medical decision.)
Why it is genuinely positive
Hot flashes disrupt sleep, work, and quality of life for millions of women, and until 2023 the effective options were essentially hormonal or off-label. A first-in-class nonhormonal treatment, proven in Phase 3 trials and approved, gives women who can't use hormones a real, purpose-built choice.
Social pulse
On Threads (searched 2026-09-22), Veozah is being discussed by the actual patient community: @reedmonixa posted "a woman going through menopause and having about the worst hot flashes does not 'meet the criteria' for Veozah? WTF (The cost of Veozah is $1998 for three months without insurance)" — genuine community discussion, though framed as frustration about prescribing criteria and cost rather than celebration. The drug is in real-world conversation among menopausal women.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Patient Care Online summary of the FDA approval (https://www.patientcareonline.com/view/fda-approves-novel-drug-for-the-treatment-of-hot-flashes-caused-by-menopause), 2023. Proves: approval date (May 12, 2023), first NK3 antagonist, Phase 3 frequency/severity reductions vs placebo.
- Social sources: Threads — @reedmonixa (genuine patient-community post discussing Veozah prescribing criteria and cost, frustrated tone). Proves: the drug is in real-world conversation among the target patient community; sentiment noted honestly.
- Positivity check: approved first-in-class nonhormonal therapy with demonstrated efficacy — genuine advance; liver-monitoring requirement noted as a caveat.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| FDA approval | May 12, 2023 (Veozah, fezolinetant) | Patient Care Online | 2023-05-12 |
| Mechanism | NK3-receptor antagonist — first nonhormonal menopause VMS treatment | Patient Care Online | 2023-05-12 |
| Trials | Phase 3: reduced frequency and severity of vasomotor symptoms vs placebo | Patient Care Online | 2023 |
| Safety note | Liver-safety labeling; baseline and periodic liver tests required (check current label) | Research notes | 2026-09-22 |
UNVERIFIED points
- Social-layer posts about Veozah were not yet observed; tier cannot be finalized until they are.
- Current liver-safety labeling details were not re-verified against the present label this session.
Sources
- Primary source: Patient Care Online summary of the FDA approval ( — retrieval date not recorded